348 related articles for article (PubMed ID: 26241675)
41. Cellular binding partners of the human papillomavirus E6 protein.
Tungteakkhun SS; Duerksen-Hughes PJ
Arch Virol; 2008; 153(3):397-408. PubMed ID: 18172569
[TBL] [Abstract][Full Text] [Related]
42. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
43. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
44. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta.
Das S; El-Deiry WS; Somasundaram K
Oncogene; 2003 Nov; 22(52):8394-402. PubMed ID: 14627980
[TBL] [Abstract][Full Text] [Related]
45. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
46. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.
Lea JS; Sunaga N; Sato M; Kalahasti G; Miller DS; Minna JD; Muller CY
Reprod Sci; 2007 Jan; 14(1):20-8. PubMed ID: 17636212
[TBL] [Abstract][Full Text] [Related]
47. Extended effects of human papillomavirus 16 E6-specific short hairpin RNA on cervical carcinoma cells.
Bai L; Wei L; Wang J; Li X; He P
Int J Gynecol Cancer; 2006; 16(2):718-29. PubMed ID: 16681752
[TBL] [Abstract][Full Text] [Related]
48. [Relationship between nitric oxide in cervical microenvironment and different HPV types and effect on cervical cancer cells].
Wei XM; Wang Q; Gao SJ; Sui L
Zhonghua Fu Chan Ke Za Zhi; 2011 Apr; 46(4):260-5. PubMed ID: 21609578
[TBL] [Abstract][Full Text] [Related]
49. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
Moon MS; Lee CJ; Um SJ; Park JS; Yang JM; Hwang ES
Gynecol Oncol; 2001 Feb; 80(2):168-75. PubMed ID: 11161855
[TBL] [Abstract][Full Text] [Related]
50. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells.
Hamada K; Sakaue M; Alemany R; Zhang WW; Horio Y; Roth JA; Mitchell MF
Gynecol Oncol; 1996 Nov; 63(2):219-27. PubMed ID: 8910631
[TBL] [Abstract][Full Text] [Related]
51. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
[TBL] [Abstract][Full Text] [Related]
52. Oncogenic human papillomaviruses block expression of the B-cell translocation gene-2 tumor suppressor gene.
Cullmann C; Hoppe-Seyler K; Dymalla S; Lohrey C; Scheffner M; Dürst M; Hoppe-Seyler F
Int J Cancer; 2009 Nov; 125(9):2014-20. PubMed ID: 19551855
[TBL] [Abstract][Full Text] [Related]
53. [Reversal effect of antisense RNA targeting human papillomavirus 16 (HPV16) E6E7 on malignancy of human cervical cancer cell line SiHa].
Sima N; Wang W; Xu Q; Tian X; Luo AY; Lu YP; Wang SX; Ma D
Ai Zheng; 2007 Jan; 26(1):26-31. PubMed ID: 17222363
[TBL] [Abstract][Full Text] [Related]
54. Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients.
Chen SP; Hsu NY; Wu JY; Chen CY; Chou MC; Lee H; Cheng YW
Ann Thorac Surg; 2013 Apr; 95(4):1196-203. PubMed ID: 23522190
[TBL] [Abstract][Full Text] [Related]
55. Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells.
Tan S; Hougardy BM; Meersma GJ; Schaap B; de Vries EG; van der Zee AG; de Jong S
Mol Pharmacol; 2012 May; 81(5):701-9. PubMed ID: 22328720
[TBL] [Abstract][Full Text] [Related]
56. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors.
Kunke D; Grimm D; Denger S; Kreuzer J; Delius H; Komitowski D; Kleinschmidt JA
Cancer Gene Ther; 2000 May; 7(5):766-77. PubMed ID: 10830724
[TBL] [Abstract][Full Text] [Related]
57. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.
Heideman DA; Steenbergen RD; van der Torre J; Scheffner M; Alemany R; Gerritsen WR; Meijer CJ; Snijders PJ; van Beusechem VW
Mol Ther; 2005 Dec; 12(6):1083-90. PubMed ID: 16085463
[TBL] [Abstract][Full Text] [Related]
58. The molecular response of vanadium complexes of nicotinoyl hydrazone in cervical cancers--a possible interference with HPV oncogenic markers.
Nair RS; Kuriakose M; Somasundaram V; Shenoi V; Kurup MR; Srinivas P
Life Sci; 2014 Oct; 116(2):90-7. PubMed ID: 25258113
[TBL] [Abstract][Full Text] [Related]
59. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
[TBL] [Abstract][Full Text] [Related]
60. Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter.
Hirao N; Iwata T; Tanaka K; Nishio H; Nakamura M; Morisada T; Morii K; Maruyama N; Katoh Y; Yaguchi T; Ohta S; Kukimoto I; Aoki D; Kawakami Y
Gynecol Oncol; 2019 Nov; 155(2):340-348. PubMed ID: 31477279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
